SensoDetect AB

11/10/2025 | Press release | Distributed by Public on 11/10/2025 11:28

SensoDetect: SensoDetect AB Announces Delegation Trip to China, 16–27 November 2025 and comments on delayed Q3 report

Press release from Companies

Publicerat: 2025-11-10 16:45:00

SensoDetect AB: SensoDetect AB Announces Delegation Trip to China, 16-27 November 2025 and comments on delayed Q3 report

SensoDetect AB (publ) will conduct a delegation visit to China from 16-30 November 2025 to progress operational, clinical and commercial workstreams tied to the Company's joint venture Beijing Mind Exploration Medical Technology Co., Ltd. ("BME") and to meet with clinical, regulatory and industrial partners in Beijing and Shenzhen. The delegation includes Johan Möllerström (Chairman), Wendi Ma (Board Member), PA Hedin (CEO), and Johan Källstrand (AI & research, external).

CEO Comment

"Our November program is tightly focused on execution in China-finalizing clinical pathways, advancing regulatory dossiers, securing scale-up for screening and connected sales and marketing activities. With our AI software now installed and tested in China and our JV capitalization completed, this trip is about turning that momentum into measurable roll-out milestones," says PA Hedin, CEO of SensoDetect AB. "The planning of this important trip and the fact that we are in China has also meant that we have delayed the Q3 report to 27 of November."

High-Level Objectives

• Consolidate clinical collaboration structures and data capture for neuro-auditory screening.

• Advance regulatory planning (including documentation alignment and local validation workstreams).

• Coordinate manufacturing readiness, quality systems, and distribution planning with Chinese partners.

• Coordinate sales and marketing activities.

Agenda (16-27 November 2025)

Beijing

• Nov 17-22: Clinical collaboration meetings; site visit program for screening partners (education & hospital channels), sales and marketing coordination. Regulatory planning workshops; JV governance and strategic partner meetings.

• Nov 23: Internal consolidation and Beijing wrap-up.

Shenzhen / Nantong

• Nov 24-26 Manufacturing & quality process reviews; ERP/ops alignment.

• Nov 27: Reporting prep and close-out; return travel.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
[email protected]

SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company's technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.

SensoDetect's core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions-providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.

In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.

SensoDetect's mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale-improving outcomes for patients, families, and society.

More info at https://www.sensodetect.com/

CisionLink
Läs som PDF
SensoDetect AB published this content on November 10, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 10, 2025 at 17:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]